

**Reference:** FOI.ICB-2324/492

**Subject:** Eye Care Spend

*I can confirm that the ICB does hold some of the information requested; please see responses below:*

QUESTION	RESPONSE																																			
<p>1) The <b>amount spent</b> by the ICB on the following companies for the period <b>1 January 2021 to 31st December 2022</b> <u>and</u> the <b>number of cataract operations purchased</b> from these same companies during this period.</p> <p>- Spamedica Ltd</p> <p>- Optegra UK Ltd</p> <p>- Anglia Eye Care Service Ltd</p>	<p>Response to questions 1-3 are in the below table. Outpatient activity is for all Ophthalmology, not just cataracts.</p> <table border="1" data-bbox="1099 970 2063 1182"> <thead> <tr> <th data-bbox="1099 970 1514 1031">Provider</th> <th colspan="2" data-bbox="1514 970 1753 1031">Inpatient</th> <th colspan="2" data-bbox="1753 970 2063 1031">Outpatient</th> </tr> <tr> <th data-bbox="1099 1031 1514 1062"></th> <th data-bbox="1514 1031 1599 1062">Cataracts</th> <th data-bbox="1599 1031 1753 1062">Ophthal Costs</th> <th data-bbox="1753 1031 1839 1062">Activity</th> <th data-bbox="1839 1031 2063 1062">Ophthal Costs</th> </tr> </thead> <tbody> <tr> <td data-bbox="1099 1062 1514 1094">SPAMEDICA (Jan-21 to Dec-22)</td> <td data-bbox="1514 1062 1599 1094">2570</td> <td data-bbox="1599 1062 1753 1094">£ 2,411,235</td> <td data-bbox="1753 1062 1839 1094">7492</td> <td data-bbox="1839 1062 2063 1094">£ 595,773</td> </tr> <tr> <td data-bbox="1099 1094 1514 1126">OPTEGRA (BIRMINGHAM EYE HOSPITAL)</td> <td data-bbox="1514 1094 1599 1126">0</td> <td data-bbox="1599 1094 1753 1126">£ -</td> <td data-bbox="1753 1094 1839 1126">0</td> <td data-bbox="1839 1094 2063 1126">£ -</td> </tr> <tr> <td data-bbox="1099 1126 1514 1158">NEWMEDICA (Mar-22 to Feb-23)</td> <td data-bbox="1514 1126 1599 1158">4045</td> <td data-bbox="1599 1126 1753 1158">£ 3,676,282</td> <td data-bbox="1753 1126 1839 1158">11775</td> <td data-bbox="1839 1126 2063 1158">£ 1,195,115</td> </tr> <tr> <td data-bbox="1099 1158 1514 1190">Anglia Eye Care Service Ltd</td> <td data-bbox="1514 1158 1599 1190">0</td> <td data-bbox="1599 1158 1753 1190">£ -</td> <td data-bbox="1753 1158 1839 1190">0</td> <td data-bbox="1839 1158 2063 1190">£ -</td> </tr> <tr> <td data-bbox="1099 1190 1514 1222">Community Health and Eye Care Ltd (CHEC)</td> <td data-bbox="1514 1190 1599 1222">0</td> <td data-bbox="1599 1190 1753 1222">£ -</td> <td data-bbox="1753 1190 1839 1222">0</td> <td data-bbox="1839 1190 2063 1222">£ -</td> </tr> </tbody> </table>	Provider	Inpatient		Outpatient			Cataracts	Ophthal Costs	Activity	Ophthal Costs	SPAMEDICA (Jan-21 to Dec-22)	2570	£ 2,411,235	7492	£ 595,773	OPTEGRA (BIRMINGHAM EYE HOSPITAL)	0	£ -	0	£ -	NEWMEDICA (Mar-22 to Feb-23)	4045	£ 3,676,282	11775	£ 1,195,115	Anglia Eye Care Service Ltd	0	£ -	0	£ -	Community Health and Eye Care Ltd (CHEC)	0	£ -	0	£ -
Provider	Inpatient		Outpatient																																	
	Cataracts	Ophthal Costs	Activity	Ophthal Costs																																
SPAMEDICA (Jan-21 to Dec-22)	2570	£ 2,411,235	7492	£ 595,773																																
OPTEGRA (BIRMINGHAM EYE HOSPITAL)	0	£ -	0	£ -																																
NEWMEDICA (Mar-22 to Feb-23)	4045	£ 3,676,282	11775	£ 1,195,115																																
Anglia Eye Care Service Ltd	0	£ -	0	£ -																																
Community Health and Eye Care Ltd (CHEC)	0	£ -	0	£ -																																
<p>2) The <b>amount spent</b> by the ICB on the following company for the period <b>1 July 2021 to 30 June 2022</b> <u>and</u> the <b>number of cataract operations purchased</b> from this company during this period.</p> <p>- Community Health and Eye Care Ltd (CHEC)</p>																																				
<p>3) The <b>amount spent</b> by the ICB on the following company (or any of its subsidiaries) for the period <b>1 March 2022 to 28 February 2023</b> <u>and</u> the <b>number of cataract operations</b></p>																																				



<p><b>purchased</b> from this company or any of its subsidiaries during this period.</p> <p>- Newmedica Systems Ltd (Newmedica)</p>	
---	--

*The information provided in this response is accurate as of 15 April 2024 and has been approved for release by Sarah Truelove, Deputy Chief Executive and Chief Finance Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.*